Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $586000.0.

  • Oncology Institute's Other Non-Current Assets fell 34.01% to $586000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $586000.0, marking a year-over-year decrease of 34.01%. This contributed to the annual value of $589000.0 for FY2024, which is 499.11% up from last year.
  • Per Oncology Institute's latest filing, its Other Non-Current Assets stood at $586000.0 for Q3 2025, which was down 34.01% from $586000.0 recorded in Q2 2025.
  • Oncology Institute's 5-year Other Non-Current Assets high stood at $875000.0 for Q4 2021, and its period low was $407000.0 during Q2 2022.
  • Its 5-year average for Other Non-Current Assets is $586875.0, with a median of $575000.0 in 2024.
  • As far as peak fluctuations go, Oncology Institute's Other Non-Current Assets surged by 61721.31% in 2021, and later crashed by 4548.57% in 2022.
  • Oncology Institute's Other Non-Current Assets (Quarter) stood at $875000.0 in 2021, then tumbled by 45.49% to $477000.0 in 2022, then increased by 17.61% to $561000.0 in 2023, then increased by 4.99% to $589000.0 in 2024, then fell by 0.51% to $586000.0 in 2025.
  • Its Other Non-Current Assets was $586000.0 in Q3 2025, compared to $586000.0 in Q2 2025 and $591000.0 in Q1 2025.